The Full Wiki

More info on Casopitant

Casopitant: Wikis

  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Casopitant
Systematic (IUPAC) name
(2S,4S)-4-(4-Acetyl-1-piperazinyl)- N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
Identifiers
CAS number  ?
ATC code A04AD13
PubChem 23725089
Chemical data
Formula C 30H35F7N4O2  
Mol. mass 616.26 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]

See also

References

  1. ^ Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.  
  2. ^ "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa". London: EMEA. 13 October 2009. http://www.emea.europa.eu/humandocs/PDFs/EPAR/zunrisa/63959809en.pdf. Retrieved 21 December 2009.  







Got something to say? Make a comment.
Your name
Your email address
Message